$6.23
1.52%
Downside
Day's Volatility :2.93%
Upside
1.42%
41.35%
Downside
52 Weeks Volatility :56.71%
Upside
26.18%
Period | Biote Corp | Index (Russel 2000) |
---|---|---|
3 Months | -6.88% | 0.0% |
6 Months | 3.32% | 0.0% |
1 Year | 24.1% | 0.0% |
3 Years | 46.93% | -22.3% |
Market Capitalization | 327.9M |
Book Value | - $4.62 |
Earnings Per Share (EPS) | 0.5 |
PE Ratio | 12.46 |
Wall Street Target Price | 9.59 |
Profit Margin | 3.67% |
Operating Margin TTM | 16.55% |
Return On Assets TTM | 20.54% |
Return On Equity TTM | 0.0% |
Revenue TTM | 187.2M |
Revenue Per Share TTM | 5.64 |
Quarterly Revenue Growth YOY | -0.2% |
Gross Profit TTM | 90.6M |
EBITDA | 39.3M |
Diluted Eps TTM | 0.5 |
Quarterly Earnings Growth YOY | 3.42 |
EPS Estimate Current Year | -0.02 |
EPS Estimate Next Year | 0.57 |
EPS Estimate Current Quarter | 0.09 |
EPS Estimate Next Quarter | 0.1 |
What analysts predicted
Upside of 53.93%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 110.0M | - |
Net Income | 21.3M | - |
Net Profit Margin | 19.36% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 116.6M | ↑ 5.99% |
Net Income | 29.2M | ↑ 36.99% |
Net Profit Margin | 25.02% | ↑ 5.66% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 139.4M | ↑ 19.58% |
Net Income | 32.6M | ↑ 11.85% |
Net Profit Margin | 23.4% | ↓ 1.62% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 165.0M | ↑ 18.34% |
Net Income | 1.3M | ↓ 95.94% |
Net Profit Margin | 0.8% | ↓ 22.6% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 185.4M | ↑ 12.37% |
Net Income | 3.3M | ↑ 150.45% |
Net Profit Margin | 1.79% | ↑ 0.99% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 44.8M | ↑ 0.8% |
Net Income | -21.4M | ↓ 267.3% |
Net Profit Margin | -47.79% | ↓ 76.58% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 49.3M | ↑ 9.84% |
Net Income | -5.1M | ↓ 76.0% |
Net Profit Margin | -10.44% | ↑ 37.35% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 45.6M | ↓ 7.51% |
Net Income | 7.5M | ↓ 246.41% |
Net Profit Margin | 16.53% | ↑ 26.97% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 45.7M | ↑ 0.32% |
Net Income | 7.7M | ↑ 2.71% |
Net Profit Margin | 16.92% | ↑ 0.39% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 46.8M | ↑ 2.41% |
Net Income | -2.1M | ↓ 126.76% |
Net Profit Margin | -4.42% | ↓ 21.34% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 49.2M | ↑ 5.05% |
Net Income | -6.3M | ↑ 205.41% |
Net Profit Margin | -12.86% | ↓ 8.44% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 23.9M | - |
Total Liabilities | 56.8M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 32.6M | ↑ 36.4% |
Total Liabilities | 49.7M | ↓ 12.6% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 54.3M | ↑ 66.72% |
Total Liabilities | 50.2M | ↑ 1.09% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 111.6M | ↑ 105.49% |
Total Liabilities | 169.9M | ↑ 238.45% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 155.3M | ↑ 39.1% |
Total Liabilities | 191.8M | ↑ 12.9% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 119.1M | ↑ 6.71% |
Total Liabilities | 202.9M | ↑ 19.44% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 139.1M | ↑ 16.72% |
Total Liabilities | 212.3M | ↑ 4.61% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 149.7M | ↑ 7.69% |
Total Liabilities | 201.0M | ↓ 5.31% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 155.3M | ↑ 3.7% |
Total Liabilities | 191.8M | ↓ 4.56% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 160.1M | ↑ 3.1% |
Total Liabilities | 205.0M | ↑ 6.86% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 92.9M | ↓ 41.98% |
Total Liabilities | 234.6M | ↑ 14.41% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 25.4M | - |
Investing Cash Flow | -1.7M | - |
Financing Cash Flow | -13.6M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 26.4M | ↑ 4.22% |
Investing Cash Flow | -1.4M | ↓ 16.69% |
Financing Cash Flow | -18.3M | ↑ 35.17% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 33.7M | ↑ 27.61% |
Investing Cash Flow | -3.8M | ↑ 173.3% |
Financing Cash Flow | -20.3M | ↑ 11.05% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 13.0M | ↑ 114.71% |
Investing Cash Flow | -380.0K | ↑ 22.19% |
Financing Cash Flow | -4.2M | ↑ 6.51% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 6.8M | ↓ 47.85% |
Investing Cash Flow | -20.8M | ↑ 5385.53% |
Financing Cash Flow | -5.1M | ↑ 19.43% |
Sell
Neutral
Buy
Biote Corp is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Biote Corp | -10.62% | 3.32% | 24.1% | 46.93% | 46.93% |
![]() Fresenius Medical Care Ag | 8.61% | -4.7% | -8.97% | -49.42% | -43.17% |
![]() Hca Holdings, Inc. | 10.14% | 19.5% | 42.7% | 53.88% | 204.27% |
![]() Tenet Healthcare Corp. | 5.44% | 56.28% | 109.05% | 104.86% | 584.82% |
![]() Universal Health Services Inc. | 8.05% | 28.98% | 78.88% | 47.48% | 53.26% |
![]() Davita Healthcare Partners Inc. | 11.94% | 11.86% | 57.31% | 14.5% | 145.19% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Biote Corp | 12.46 | 12.46 | NA | -0.02 | 0.0 | 0.21 | NA | -4.62 |
![]() Fresenius Medical Care Ag | 19.68 | 19.68 | 0.4 | 2.33 | 0.05 | 0.03 | 0.03 | 47.48 |
![]() Hca Holdings, Inc. | 18.65 | 18.65 | 1.2 | 22.56 | 0.74 | 0.11 | 0.01 | -6.17 |
![]() Tenet Healthcare Corp. | 5.9 | 5.9 | 0.83 | 10.57 | 0.55 | 0.07 | NA | 36.27 |
![]() Universal Health Services Inc. | 17.57 | 17.57 | 1.87 | 15.96 | 0.15 | 0.06 | 0.0 | 97.21 |
![]() Davita Healthcare Partners Inc. | 15.82 | 15.82 | 1.49 | 9.69 | 0.45 | 0.07 | NA | 7.44 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Biote Corp | Buy | $327.9M | 46.93% | 12.46 | 3.67% |
![]() Fresenius Medical Care Ag | Hold | $11.6B | -43.17% | 19.68 | 2.73% |
![]() Hca Holdings, Inc. | Buy | $102.6B | 204.27% | 18.65 | 8.4% |
![]() Tenet Healthcare Corp. | Buy | $15.5B | 584.82% | 5.9 | 13.18% |
![]() Universal Health Services Inc. | Hold | $16.0B | 53.26% | 17.57 | 6.22% |
![]() Davita Healthcare Partners Inc. | Hold | $12.6B | 145.19% | 15.82 | 6.86% |
Insights on Biote Corp
Revenue is up for the last 4 quarters, 45.55M → 49.16M (in $), with an average increase of 2.5% per quarter
Netprofit is down for the last 3 quarters, 7.73M → -6.32M (in $), with an average decrease of 166.1% per quarter
In the last 1 year, Tenet Healthcare Corp. has given 109.0% return, outperforming this stock by 84.9%
325 Capital LLC
Bandera Partners LLC
BlackRock Inc
Vanguard Group Inc
Wasatch Advisors LP
Boston Partners Global Investors, Inc
Organization | Biote Corp |
Employees | 194 |
CEO | Mr. Marc D. Beer |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$6.23
-0.16%
Keyarch Acquisition Corp
$6.23
-0.16%
Connexa Sports Technologies Inc
$6.23
-0.16%
Us Value Etf
$6.23
-0.16%
First Wave Biopharma Inc
$6.23
-0.16%
Global X Msci Next Emerging
$6.23
-0.16%
Fat Projects Acquisition Corp
$6.23
-0.16%
Capital Link Global Fintech
$6.23
-0.16%
Applied Uv Inc
$6.23
-0.16%